The global levofloxacin market is anticipated to grow at a significant CAGR of 5.5% during the forecast period. Levofloxacin is a bacterial antibiotic that is used to treat a number of ailments. It works by preventing bacteria from growing. The rise in bacterial infectious disease cases is driving the levofloxacin market growth. The growing number of prostate diseases across the globe also boosts the market for levofloxacin, According to WHO, Prostate cancer affects about 1 in every 8 men at some point in their lives. The most common cause of pneumonia in children is Streptococcus pneumonia. Pneumonia is the infectious cause of death in children. For instance, according to World Health Organization (WHO), Pneumonia is responsible for 14% of all deaths in children under the age of five, killing 740 180 children in 2019 and the death rates are highest in South Asia and sub-Saharan Africa. The market has been encouraged by the high prevalence of antibiotic-resistance infections and the rise of multi-drug resistant bacteria.

Impact of COVID-19 Pandemic on Global LevofloxacinMarket

The COVID-19 pandemic had impacted the global levofloxacin market significantly owning to the lockdown in most of nations to control the spread of the virus. It affected the overall demand for levofloxacin in the market. The sales of levofloxacin were affected as a result of the COVID-19 pandemic's influence on overall medical diagnosis and treatment services as the focus was shifted towards COVID essentials.

Segmental Outlook 

The global levofloxacin market is segmented based on type and application. Based on the type, the market is sub-segmented into 250MG, 500MG, and 750MG. Based on the application, the market is sub-segmented into pneumonia, skin infection, kidney infection, and bladder infection. Among these, the hospital pharmacy dominated the levofloxacin market throughout the anticipated period. As hospital pharmacies store a wider range of pharmaceuticals, including more specialist and exploratory medications, they are able to provide better service. It includes all dose forms and instructions for using levofloxacin correctly.

Global Levofloxacin Market Share by Infection Type, 2021 (%)

The Skin Infection Segment Holds the Major Share in the Global Levofloxacin Market

The skin infection segment holds the major market share and is anticipated to grow significantly during the forecast period in the global levofloxacin market in the infection-type segment. According to WHO, Scabies affects an estimated 200 million people globally at any given time. Levofloxacin is primarily used to treat difficult skin and skin structure infections caused by methicillin-susceptible Staphylococcus aureus, enterococcus faecalis, streptococcus pyogenes, Proteus mirabilis, and other bacteria. Abscesses, cellulitis, furuncles, impetigo, pyoderma, wound infections, and other skin diseases are among the most common. For instance, in 2017, According to the Global Report on Epidemiology, due to sepsis was estimated that it had affected 49 million individuals and was related to approximately 11 million potentially avoidable deaths globally. 

Regional Outlooks

The global Levofloxacin market is further segmented based on geography including North America (the US, and Canada), Europe (Italy, Spain, Germany, France, and Others), Asia-Pacific (India, China, Japan, South Korea, and Others), and the Rest of the World (the Middle East &Africa, and Latin America). Among the regions, the Asia Pacific is anticipated to hold a significant share in the market followed by North America, and then Europe.

Global Levofloxacin Market Growth, by Region 2022-2028

The Asia-Pacific RegionExpected to Hold Considerable Share in the Global Levofloxacin Market

The Asia-Pacific region holds the major share and is anticipated to grow fastest during the forecast period in the levofloxacin market. The presence of emerging countries such as China, Japan, India, and South Korea are taking big initiatives to fuel up the overall levofloxacin market. Throughout the projection period, Asia-Pacific is expected to increase at an exponential rate. The rising frequency of pneumococcal disease, unmet patient demands, increased cases of antibiotic resistance, and a rise in disorders leading to weaker immune systems are all factors contributing to the region's expansion. Additionally, some of the major companies in this market belong to this region such as Aden healthcare, Sun pharmaceutical Pvt. Ltd., Allenge India Pharma, and Bestochem.

Market Players Outlook

The major companies serving the global levofloxacinmarket include Aden Healthcare, Allenge India Pharma, Alna Biotech Pvt. Ltd., Bestochem, DivineSavior.in, and others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers & acquisitions, collaborations, funding, and new product launches, to stay competitive in the market. For instance in June 2020, Sanofi collaborated with Translate Bio to develop mRNA vaccines for a variety of infectious diseases. Sanofi will be granted exclusive global rights to develop, manufacture, and market infectious disease vaccines based on Translate Bio technology.Translate Bio's superior mRNA technology and manufacturing will be combined with Sanofi's world-class vaccine development and distribution in this expanded agreement.

The Report Covers

• Market value data analysis of 2021 and forecast to 2028.
• Annualized market revenues ($ million) for each market segment.
• Country-wise analysis of major geographical regions.
• Key companies operating in the global levofloxacinmarket. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.
• Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
• Analysis of market entry and market expansion strategies.
• Competitive strategies by identifying ‘who-stands-where’ in the market.